GnRH agonists are commonly used for short-term uterine leiomyoma treatment before surgery but, unlike relugolix, require parenteral administration, may cause temporary worsening of symptoms, and typically take 3–4 weeks before a therapeutic effect emerges [1, 3, 8, 9]. The gene discussed is GNRH1; the disease is Uterine leiomyoma.